Traumatic Brain Injury (TBI) Treatment
Ronopterin – treatment to reduce traumatic brain damage and improve patient outcomes. To date, we are still lacking a specific drug to treat the acute and long-term devastating consequences of traumatic brain injury.
Most popular related searches
traumatic brain injury
brain injury
brain damage
neurology recovery
critical care
neurology
physiological medical
medical treatment
- Ronopterin addresses this unmet medical need as iNOS inhibition
- reduces the severity and progression of damage during the acute phase
- decreases the aggressiveness of the basic treatment during the critical care phase
- improves neurologic recovery over time
- increases quality of life over time
- Worldwide approx. 60 million patients suffer from TBI annually.
- TBI is a major cause of death and disability mainly affecting young males, mostly victims of motor vehicle accidents. Among the elderly, falls are amongst the most frequent causes.
- More than 50% of the patients have to endure the long-term debilitating psychological and physiological consequences.
- The direct medical costs for the treatment of patients suffering from a TBI are tremendous.
- The most significant economic burden results from indirect costs such as loss of productivity, reduction of quality of life, disability, and the necessity for relatives to provide – sometimes life-long – care for a patient.
- The global costs of care and consequences of TBI amount to an estimated 400 billion USD.
- The high economic burden and undermet medical need account for a market potential of 1 bn USD annually by 2030.